Genmab A/S Completes Share Buy-back Program

Genmab A/S announced the completion of its share buy-back program on March 13, 2026. The program, initiated on February 17, 2026, aimed to repurchase up to 342,130 shares with a total value of 725 million DKK to fulfill commitments under the Restricted Stock Unit program. Transactions executed between March 9 and March 13, 2026, involved the repurchase of 93,130 shares for a total of 162,516,381 DKK. Following these transactions, Genmab holds 2,859,663 treasury shares, representing 4.45% of the total share capital. The program was conducted in accordance with MAR and the Safe Harbour Regulation. Genmab is an international biotechnology company focused on developing innovative antibody medicines for cancer and other serious diseases.